Entries by oslocancer

Funding Innovation in BioPharma and IT

What kind of work does it take to receive PERMIDES funding for innovative concepts and projects? Meet one of the companies that just received funding.    22 collaboration projects will receive a total of 1,25 Million Euros from PERMIDES for innovation projects between small and medium sized enterprises (SMEs) from biopharma, bioinformatics and the IT […]

Doing More in Prognosis and Diagnosis

The project DoMore! aims to achieve better and faster diagnosis and prognosis with information and communication technology solutions.    Technological innovation brightens the future ahead. With an increase in investment towards these areas, we create not only further potential in the technological field, but see betterment in the area it was produced for – such […]

How Cancer Research Becomes a Company

The Department of Cellular Therapy is great at transforming cancer research into new companies. The latest spin-out is Zelluna.   The Department of Cellular Therapy at the Radium Hospital, Oslo University Hospital, features one of Europe’s largest and most modern good manufacturing practice (GMP) facilities for cellular products. Head of the department is Prof. Gunnar Kvalheim. They […]

International Collaboration in Cancer Innovation

24 oncology innovators from 9 international hubs attended the 6th International Cancer Cluster Showcase in San Diego.   The International Cancer Cluster Showcase (ICCS) was born back in 2011 in Washington DC, during the world’s largest biotech conference, BIO International Convention. International cluster managers and representatives from the oncology field in Boston, Toulouse and Oslo […]

Our International Work

Oslo Cancer Cluster aims to enhance the visibility of oncology innovation made in Norway by being a significant partner for international clusters, global biopharma companies and academic centres. – Our goal is to support our members in their effort to attract international partners, investments and successful academia-industry collaborations, says International Advisor Jutta Heix. Heix is […]

New Board Members

Our newest board members are officially introduced!  On the 24th of May in 2017, the general assembly meeting took place and fatefully decided Oslo Cancer Cluster’s newest board members. These members, despite having some big seats to fill, will take on a respectful duty belonging to the board: where professionals in the field function as the […]

How Our Genes Will Change Cancer

Doctors, researchers and audience gather at breakfast to learn about genetics, data and how working together will help beat cancer. The time is 8:15. Many have started to file in and shuffle to their seats while chatting and occasionally sipping their first morning coffee. As it starts to quiet down, the lights are dimmed, the […]

A Constant State of Liveliness

A driving force behind the collaboration between Ullern Upper Secondary School and Oslo Cancer Cluster is stepping down. This is her adventure. After fifteen great and productive years at Ullern Upper Secondary School, Esther Eriksen steps down from her position as vice principle in the upcoming month. Esther, who has been responsible for many various […]

Helping biotech companies through innovative IT solutions

The cluster-to-cluster project PERMIDES stimulates collaboration between biotech companies and IT companies. Its goal is to develop more innovative, personalized cancer treatments.   Oslo Cancer Cluster is currently involved in a big European collaboration through the cluster-to-cluster project PERMIDES. 24 May you can benefit from the project by joining the BIOMED INFORMATICS workshop in Oslo. This workshop […]

Vi vant Siva-prisen 2017!

Oslo Cancer Cluster Incubator stakk av med Siva-prisen for 2017 på årets Siva-konferanse i Trondheim. Slik beskriver Siva vinneren: Oslo Cancer Cluster Incubator er en pådriver til utvikling av diagnostikk og behandling av kreftpasienter ved hjelp av ny revolusjonerende teknologi. De jobber med å omsette kreftforskning til nye medisiner og behandlingsformer. Dette gir nytt håp for kreftpasienter og […]